Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Merck Animal Health is investing $895 million in a De Soto new facility, which will bring hundreds of jobs. It’s a huge economic investment for the company, and the small town.

Researchers analyzed long-term survival of women diagnosed with low-risk cervical cancer, from 2010 through 2017, who ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...